S&P Futures
5,882.75 -13.50 (-0.23%) Dow Futures
43,088.00 -89.00 (-0.21%) Nasdaq Futures
20,453.75 -65.75 (-0.32%) Russell 2000 Futures
2,246.20 -9.30 (-0.41%) Crude Oil
70.35 -0.21 (-0.30%) Gold
2,749.10 +10.20 (+0.37%)
LENZ Therapeutics, Inc. (LENZ)
After hours:
- GlobeNewswire
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) fo
- GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced presentations featuring LNZ100 at multiple upcoming ophthalmology and optometry medical conferences, including Eyecelerator at the 2024 American Academy of Ophthalmology (AAO) Annual Meeting on October 17,
